Browse by author
Lookup NU author(s): Dr Othman AlmusaimiORCiD
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
The United States Food and Drug Administration (FDA) has approved a plethora of peptide-based drugs as effective drugs in cancer therapy. Peptides possess high specificity, permeability, target engagement, and a tolerable safety profile. They exhibit selective binding with cell surface receptors and proteins, functioning as agonists or antagonists. They also serve as imaging agents for diagnostic applications or can serve a dual-purpose as both diagnostic and therapeutic (theragnostic) agents. Therefore, they have been exploited in various forms, including linkers, peptide conjugates, and payloads. In this review, the FDA-approved prostate-specific membrane antigen (PSMA) peptide antagonists, peptide receptor radionuclide therapy (PRRT), somatostatin analogs, antibody–drug conjugates (ADCs), gonadotropin-releasing hormone (GnRH) analogs, and other peptide-based anticancer drugs are analyzed in terms of their chemical structures and properties, therapeutic targets and mechanisms of action, development journey, administration routes, and side effects.
Author(s): Al Musaimi O
Publication type: Article
Publication status: Published
Journal: Cancers
Year: 2024
Volume: 16
Issue: 5
Print publication date: 02/03/2024
Online publication date: 02/03/2024
Acceptance date: 01/03/2024
Date deposited: 10/04/2024
ISSN (electronic): 2072-6694
Publisher: MDPI
URL: https://doi.org/10.3390/cancers16051032
DOI: 10.3390/cancers16051032
Data Access Statement: Not applicable.
Altmetrics provided by Altmetric
